Abstract
The invention relates to purified vaccine preparations and methods for providing them. Provided is a method for providing purified viral particles of SFV, comprising the steps of i) providing a preparation of SFV replicon particles; ii) subjecting said preparation to an endonuclease treatment under conditions allowing for degradation of exogenous/host cell DNA and RNA; iii) bringing said endonuclease-treated preparation with a zwitterionic buffer solution to a conductivity of up to about 5.5 mS/cm; iv) contacting the preparation obtained in step (iii) with a strong anion exchange resin; v) eluting the bound SFV replicon particles from said anion exchange resin; vi) bringing the eluted SFV particles to a conductivity in the range of 7.0 to 9.0 mS/cm; vii) contacting the preparation obtained in step (vi) with a strong cation exchange resin under conditions and for a time sufficient to bind to said resin; viii) eluting the bound SFV replicon particles from said cation exchange resin with a zwitterionic buffer solution and collecting at least one fraction containing purified SFV replicon particles; and ix) stabilizing the at least one purified fraction by adding human serum albumin (HSA) to a final concentration in the range of about 0.5 - 2 w/v%, preferably about 1 w/v%.
Original language | English |
---|---|
Patent number | WO2020162752 |
Priority date | 08/02/2019 |
Filing date | 07/02/2020 |
Publication status | Published - 13-Aug-2020 |